BioMarin Pharmaceutical Overview
- Year Founded
-
1997
- Status
-
Public
- Employees
-
3,040
- Stock Symbol
-
BMRN
- Investments
-
16
- Share Price
-
$59.41
- (As of Monday Closing)
BioMarin Pharmaceutical General Information
Description
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
Contact Information
Website
www.biomarin.comCorporate Office
- 770 Lindaro Street
- San Rafael, CA 94901
- United States
Corporate Office
- 770 Lindaro Street
- San Rafael, CA 94901
- United States
BioMarin Pharmaceutical Timeline
BioMarin Pharmaceutical Stock Performance
As of 19-May-2025, BioMarin Pharmaceutical’s stock price is $59.41. Its current market cap is $11.4B with 192M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $59.41 | $59.27 | $52.93 - $94.85 | $11.4B | 192M | 1.8M | $2.75 |
BioMarin Pharmaceutical Financials Summary
As of 31-Mar-2025, BioMarin Pharmaceutical has a trailing 12-month revenue of $2.95B.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 12,951,036 | 12,199,265 | 18,131,922 | 19,050,995 |
| Revenue | 2,950,227 | 2,853,915 | 2,419,226 | 2,096,039 |
| EBITDA | 702,574 | 575,645 | 248,434 | 247,325 |
| Net Income | 523,883 | 426,859 | 167,645 | 141,561 |
| Total Assets | 7,147,007 | 6,988,940 | 6,841,603 | 6,375,074 |
| Total Debt | 601,959 | 602,712 | 1,095,751 | 1,093,394 |
BioMarin Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
BioMarin Pharmaceutical Comparisons
Industry
Financing
Details
BioMarin Pharmaceutical Competitors (36)
One of BioMarin Pharmaceutical’s 36 competitors is Alnylam Pharmaceuticals, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Biogen | Formerly VC-backed | Cambridge, MA | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA | ||||
| Regeneron Pharmaceuticals | Formerly VC-backed | Tarrytown, NY | ||||
| Pfizer Pakistan | Corporation | Karachi, Pakistan |
BioMarin Pharmaceutical Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
BioMarin Pharmaceutical Patents
BioMarin Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240368596-A1 | Dystrophin exon skipping oligonucleotides | Pending | 05-May-2023 | ||
| US-20230416741-A1 | Method of treating duchenne muscular dystrophy | Pending | 05-May-2022 | ||
| AU-2023265665-A1 | Method of treating duchenne muscular dystrophy | Pending | 05-May-2022 | ||
| EP-4519439-A1 | Method of treating duchenne muscular dystrophy | Pending | 05-May-2022 | ||
| US-20230348909-A1 | Dystrophin exon skipping oligonucleotides | Pending | 30-Mar-2022 | C12N15/113 |
BioMarin Pharmaceutical Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
BioMarin Pharmaceutical Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
BioMarin Pharmaceutical Investments & Acquisitions (16)
BioMarin Pharmaceutical’s most recent deal was a Merger/Acquisition with Inozyme Pharma for . The deal was made on 16-May-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Inozyme Pharma | 16-May-2025 | Merger/Acquisition | Drug Discovery | ||
| Dinaqor | 03-May-2020 | Corporate | Biotechnology | ||
| Merck Serono & BioMarin Pharmaceutical (Kuvan Rights) | 01-Oct-2015 | Corporate Asset Purchase | Buildings and Property | ||
| Prosensa | 29-Jan-2015 | Merger/Acquisition | Biotechnology | ||
| Zacharon Pharmaceuticals | 04-Jan-2013 | Merger/Acquisition | Pharmaceuticals |
BioMarin Pharmaceutical ESG
Risk Overview
Risk Rating
Updated May, 31, 2024
23.45 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,631
Rank
Percentile
Pharmaceuticals
Industry
of 843
Rank
Percentile
Biotechnology
Subindustry
of 365
Rank
Percentile
BioMarin Pharmaceutical Exits (1)
BioMarin Pharmaceutical’s most recent exit was on 16-Jan-2009 from La Jolla Pharmaceutical. The exit was categorized as with 3 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| La Jolla Pharmaceutical | 16-Jan-2009 | Completed |
|
BioMarin Pharmaceutical FAQs
-
When was BioMarin Pharmaceutical founded?
BioMarin Pharmaceutical was founded in 1997.
-
Where is BioMarin Pharmaceutical headquartered?
BioMarin Pharmaceutical is headquartered in San Rafael, CA.
-
What is the size of BioMarin Pharmaceutical?
BioMarin Pharmaceutical has 3,040 total employees.
-
What industry is BioMarin Pharmaceutical in?
BioMarin Pharmaceutical’s primary industry is Pharmaceuticals.
-
Is BioMarin Pharmaceutical a private or public company?
BioMarin Pharmaceutical is a Public company.
-
What is BioMarin Pharmaceutical’s stock symbol?
The ticker symbol for BioMarin Pharmaceutical is BMRN.
-
What is the current stock price of BioMarin Pharmaceutical?
As of 19-May-2025 the stock price of BioMarin Pharmaceutical is $59.41.
-
What is the current market cap of BioMarin Pharmaceutical?
The current market capitalization of BioMarin Pharmaceutical is $11.4B.
-
What is BioMarin Pharmaceutical’s current revenue?
The trailing twelve month revenue for BioMarin Pharmaceutical is $2.95B.
-
Who are BioMarin Pharmaceutical’s competitors?
Alnylam Pharmaceuticals, Biogen, Sangamo Therapeutics, Regeneron Pharmaceuticals, and Pfizer Pakistan are some of the 36 competitors of BioMarin Pharmaceutical.
-
What is BioMarin Pharmaceutical’s annual earnings per share (EPS)?
BioMarin Pharmaceutical’s EPS for 12 months was $2.75.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
